Loading organizations...
§ Private Profile · 4040 Macarthur Blvd Ste 310, Newport Beach, California, 92660, United States
A lifestyle healthcare company providing software, practice growth services, and patient financing for elective medical specialties.
Alphaeon is an Irvine, California-based lifestyle healthcare and health-technology company that provides software, practice management services, and patient financing solutions for self-pay elective medical procedures. The organization focuses on specialties not typically covered by insurance, such as plastic surgery, dermatology, and ophthalmology, connecting patients with board-certified providers through its ShoutMD platform. The company has built a network of over 4,500 physicians, representing approximately 40 percent of plastic surgeons, 38 percent of refractive ophthalmologists, and 21 percent of dermatologists in its target markets. Operating as a corporate subsidiary, the enterprise has secured financial backing from institutional investors including Sailing Capital, Chow Tai Fook Enterprises, and Longitude Capital, while partnering with Comenity Capital Bank for its credit services. Alphaeon was originally founded in 2013 by entrepreneur Robert E. Grant and private equity firm Strathspey Crown.
Alphaeon has raised $107.0M across 2 funding rounds.
Alphaeon has raised $107.0M in total across 2 funding rounds.
Alphaeon has raised $107.0M in total across 2 funding rounds.
Alphaeon's investors include Longitude Capital, Chow Tai Fook Enterprises, H&S Ventures, Sailing Capital.
Alphaeon has raised $107.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in November 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2015 | $80M Series B | — | Longitude Capital, Chow TAI Fook Enterprises, H&S Ventures, Sailing Capital | Announced |
| Jan 1, 2015 | $27M Series A | — | Longitude Capital | Announced |
Alphaeon Corporation is a healthcare technology company that provides financing solutions, primarily through its Alphaeon Credit platform, to patients seeking elective procedures in self-pay segments like plastic surgery, ophthalmology, dentistry, and dermatology.[1][2][3] It serves healthcare providers by offering user-friendly credit options with high approval rates, superior credit limits, and quick application processes (under 5 minutes), enabling practices to help more patients afford treatments without impacting credit scores initially.[1][3] As a subsidiary of private equity firm Strathspey Crown LLC, Alphaeon focuses on bridging financial gaps in aesthetic and medical care, with reported revenue around $36 million and total funding of $107.4 million across five rounds.[2]
Alphaeon Corporation was founded in July 2013 by Robert E. Grant, its former CEO, as a wholly owned subsidiary of Strathspey Crown LLC, a Newport Beach-based private equity firm.[1] Headquartered initially in Irvine, California (with some sources noting Newport Beach), the company emerged to address financing needs in elective healthcare, targeting self-pay markets underserved by traditional lending.[1][2] A pivotal moment came in January 2020, when Alphaeon reorganized into two units: AEON Biopharma, Inc. (focused on biopharma) and Alphaeon1 LLC (operating as Alphaeon Credit for financing).[1] This split sharpened its focus on credit services, building early traction through provider partnerships that praised its simplicity and customer service.[3]
Alphaeon rides the wave of fintech-healthcare convergence, capitalizing on rising demand for elective, cash-pay procedures amid growing consumer spending on aesthetics and wellness—segments projected to expand with aging populations and social media-driven beauty standards.[1][2] Its timing aligns with post-2020 shifts toward specialized financing as traditional insurance lags in covering cosmetics and electives, while market forces like high patient out-of-pocket costs (exacerbated by inflation) favor accessible credit solutions.[3] By empowering thousands of practices, Alphaeon influences the ecosystem through higher procedure volumes, fostering innovation in provider-patient financial tools and indirectly supporting medtech growth in underserved specialties.[1][3]
Alphaeon is poised to expand its credit platform amid booming elective healthcare demand, potentially integrating AI-driven approvals or partnerships with telehealth for broader reach. Trends like personalized medicine financing and rising self-pay volumes (fueled by wellness booms) will shape its path, with its provider-first model driving adoption. Its influence may evolve from niche financier to ecosystem enabler, especially if it scales beyond current segments—building on its reorganization momentum to capture more of the $50B+ U.S. aesthetics market. This positions Alphaeon as a quiet powerhouse in healthcare fintech, much like its origins in solving real provider pain points.